• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Havrix 720 Junior
    / GSK

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    1 X 0.5 ml/vial

    not in the basket chart 76515 8210

    Related information


    This vaccine should be injected intramuscularly in the deltoid muscle. The vaccine should never be administered intravenously.
    Children/adolescents (1-15 years): Primary immunisation consists of a single dose given intramuscularly. This provides anti-HAV antibodies for at least one year. This vaccine confers protection against hepatitis A within two to four weeks. In order to obtain more persistent immunity, for at least 10 years, a booster dose is recommended between 6 and 12 months after primary immunisation. Booster vaccination delayed up to 3 years after the primary dose induces similar antibody levels as a booster dose administered within the recommended time interval. Current recommendations do not support the need for further booster vaccination among immunocompetent subjects after a 2-dose vaccination course. Can be used as a booster in subjects previously immunised with any inactivated hepatitis A vaccine. In the event of a subject being exposed to a high risk of contracting hepatitis A within two weeks of the primary immunisation dose, human normal immunoglobulin may be given simultaneously with this vaccine at different injection sites.
    Method of administration: The vaccine should be injected intramuscularly in the deltoid muscle.
    The vaccine should never be administered intravenously.


    Active immunisation against HAV infection from 1 year up to and including 15 years of age. The vaccine is particularly indicated for those at increased risk of infection or transmission.


    Hypersensitivity to the active substance, to any of the excipients.

    Special Precautions

    Immunisation should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.
    As for all vaccines, appropriate medication e.g. epinephrine (adrenaline) should be readily available for immediate use in case of anaphylaxis.
    It is possible that subjects may be in the incubation period of a hepatitis A infection at the time of immunisation. It is not known whether this vaccine will prevent hepatitis A in such cases.
    In haemodialysis patients and in subjects with an impaired immune system, adequate anti-HAV antibody titres may not be obtained after the primary immunisation and such patients may therefore require administration of additional doses of vaccine. Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

    Side Effects

    Appetite lost, Headache, Drowsiness.
    See prescribing information for full details.

    Drug interactions

    Simultaneous administration of this vaccine with normal immunoglobulin does not influence the seroconversion rate to this vaccine , however, it may result in a lower antibody titre. A similar effect could be observed with this vaccine.
    Preliminary data on the concomitant administration of Havrix, at a dose of 720 ELISA units/ml, with recombinant hepatitis B virus vaccine suggests that there is no interference in the immune response to either antigen. When concomitant administration is considered necessary the vaccines must be given at different injection sites. This vaccine  must not be mixed with other vaccines in the same syringe.

    Pregnancy and Lactation

    Pregnancy: There are no or limited amount of data from the use of this vaccine in pregnant women.
    Lactation: It is unknown whether this vaccine is excreted in human milk.
    See prescribing information for full details.


    Cases of overdose have been reported during post-marketing surveillance. Adverse events reported following overdosage were similar to those reported with normal vaccine administration.

    Important notes

    Storage: Store at 2Ċ- 8Ċ in a refrigerator. Store in original pack. Do not freeze.

    GlaxoSmithKline Biologicals S.A., Rixensart, Belgium